Literature DB >> 2049245

Disposition and metabolism of codeine after single and chronic doses in one poor and seven extensive metabolisers.

Z R Chen1, A A Somogyi, G Reynolds, F Bochner.   

Abstract

1. The pharmacokinetics, metabolism and partial clearances of codeine to morphine, norcodeine and codeine-6-glucuronide after single (30 mg) and chronic (30 mg 8 h for seven doses) administration of codeine were studied in eight subjects (seven extensive and one poor metaboliser of dextromethorphan). Codeine, codeine-6-glucuronide, morphine and norcodeine were measured by high performance liquid chromatographic assays. 2. After the single dose, the time to achieve maximum plasma codeine concentrations was 0.97 +/- 0.31 h (mean +/- s.d.) and for codeine-6-glucuronide it was 1.28 +/- 0.49 h. The plasma AUC of codeine-6-glucuronide was 15.8 +/- 4.5 times higher than that of codeine. The AUC of codeine in saliva was 3.4 +/- 1.1 times higher than that in plasma. The elimination half-life of codeine was 3.2 +/- 0.3 h and that of codeine-6-glucuronide was 3.2 +/- 0.9 h. 3. The renal clearance of codeine was 183 +/- 59 ml min-1 and was inversely correlated with urine pH (r = 0.81). These data suggest that codeine undergoes filtration at the glomerulus, tubular secretion and passive reabsorption. The renal clearance of codeine-6-glucuronide was 55 +/- 21 ml min-1, and was not correlated with urine pH. Its binding to human plasma was less than 10%. These data suggest that codeine-6-glucuronide undergoes filtration at the glomerulus and tubular reabsorption. This latter process is unlikely to be passive. 4. After chronic dosing, the pharmacokinetics of codeine and codeine-6-glucuronide were not significantly different from the single dose pharmacokinetics. 5. After the single dose, 86.1 +/- 11.4% of the dose was recovered in urine, of which 59.8 +/- 10.3% was codeine-6-glucuronide, 7.1 +/- 1.1% was total morphine, 6.9 +/- 2.1% was total norcodeine and 11.8 +/- 3.9% was unchanged codeine. These recoveries were not significantly different (P greater than 0.05) after chronic administration. 6. After the single dose, the partial clearance to morphine was 137 +/- 31 ml min-1 in the seven extensive metabolisers and 8 ml min-1 in the poor metaboliser; to norcodeine the values were 103 +/- 33 ml min-1 and 90 ml min-1; to codeine-6-glucuronide the values were 914 +/- 129 ml min-1 and 971 ml min-1; and intrinsic clearance was 1568 +/- 103 ml min-1 and 1450 ml min-1. These values were not significantly (P greater than 0.05) altered by chronic administration.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2049245      PMCID: PMC1368322          DOI: 10.1111/j.1365-2125.1991.tb05550.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  38 in total

1.  Morphine-6-glucuronide, a potent mu agonist.

Authors:  G W Pasternak; R J Bodnar; J A Clark; C E Inturrisi
Journal:  Life Sci       Date:  1987-12-28       Impact factor: 5.037

2.  Pharmacokinetics and pharmacodynamics of codeine in end-stage renal disease.

Authors:  D R Guay; W M Awni; J W Findlay; C E Halstenson; P A Abraham; J A Opsahl; E C Jones; G R Matzke
Journal:  Clin Pharmacol Ther       Date:  1988-01       Impact factor: 6.875

3.  Polymorphic drug oxidation: pharmacokinetic basis and comparison of experimental indices.

Authors:  P R Jackson; G T Tucker; M S Lennard; H F Woods
Journal:  Br J Clin Pharmacol       Date:  1986-11       Impact factor: 4.335

4.  Plasma concentrations of codeine and its metabolite, morphine, after single and repeated oral administration.

Authors:  H Quiding; P Anderson; U Bondesson; L O Boréus; P A Hynning
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

5.  Morphine metabolism: does the renal hypothesis hold water?

Authors:  G W Hanks; G W Aherne
Journal:  Lancet       Date:  1985-01-26       Impact factor: 79.321

6.  Morphine-6-glucuronide, an important factor in interpreting morphine radioimmunoassays.

Authors:  G W Aherne; P Littleton
Journal:  Lancet       Date:  1985-07-27       Impact factor: 79.321

7.  Determination of morphine, morphine-3-glucuronide and (tentatively) morphine-6-glucuronide in plasma and urine using ion-pair high-performance liquid chromatography.

Authors:  J O Svensson; A Rane; J Säwe; F Sjöqvist
Journal:  J Chromatogr       Date:  1982-07-09

8.  Comparative disposition of codeine and pholcodine in man after single oral doses.

Authors:  J W Findlay; A S Fowle; R F Butz; E C Jones; B C Weatherley; R M Welch; J Posner
Journal:  Br J Clin Pharmacol       Date:  1986-07       Impact factor: 4.335

9.  Codeine disposition in smokers and nonsmokers.

Authors:  J F Rogers; J W Findlay; J H Hull; R F Butz; E C Jones; J A Bustrack; R M Welch
Journal:  Clin Pharmacol Ther       Date:  1982-08       Impact factor: 6.875

10.  Sparteine oxidation is practically abolished in quinidine-treated patients.

Authors:  R Brinn; K Brøsen; L F Gram; T Haghfelt; S V Otton
Journal:  Br J Clin Pharmacol       Date:  1986-08       Impact factor: 4.335

View more
  25 in total

1.  Analgesic and immunomodulatory effects of codeine and codeine 6-glucuronide.

Authors:  V Srinivasan; D Wielbo; J Simpkins; J Karlix; K Sloan; I Tebbett
Journal:  Pharm Res       Date:  1996-02       Impact factor: 4.200

Review 2.  The pharmacotherapy of chronic pain: a review.

Authors:  Mary E Lynch; C Peter N Watson
Journal:  Pain Res Manag       Date:  2006       Impact factor: 3.037

3.  Lack of effect of paracetamol on the pharmacokinetics and metabolism of codeine in man.

Authors:  A Somogyi; F Bochner; Z R Chen
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

Review 4.  Role of active metabolites in the use of opioids.

Authors:  Janet K Coller; Lona L Christrup; Andrew A Somogyi
Journal:  Eur J Clin Pharmacol       Date:  2008-10-29       Impact factor: 2.953

5.  Blood-brain barrier equilibration of codeine in rats studied with microdialysis.

Authors:  R Xie; M Hammarlund-Udenaes
Journal:  Pharm Res       Date:  1998-04       Impact factor: 4.200

Review 6.  Pharmacokinetics of opioids in liver disease.

Authors:  I Tegeder; J Lötsch; G Geisslinger
Journal:  Clin Pharmacokinet       Date:  1999-07       Impact factor: 6.447

Review 7.  Transporter-Mediated Disposition of Opioids: Implications for Clinical Drug Interactions.

Authors:  Robert Gharavi; William Hedrich; Hongbing Wang; Hazem E Hassan
Journal:  Pharm Res       Date:  2015-05-14       Impact factor: 4.200

8.  Application of Model Informed Precision Dosing to Address the Impact of Pregnancy Stage and CYP2D6 Phenotype on Foetal Morphine Exposure.

Authors:  Sarah Badaoui; Ashley M Hopkins; A David Rodrigues; John O Miners; Michael J Sorich; Andrew Rowland
Journal:  AAPS J       Date:  2021-01-06       Impact factor: 4.009

9.  Nicotine Increases Codeine Analgesia Through the Induction of Brain CYP2D and Central Activation of Codeine to Morphine.

Authors:  Douglas M McMillan; Rachel F Tyndale
Journal:  Neuropsychopharmacology       Date:  2015-01-29       Impact factor: 7.853

10.  Influence of the CYP2D6 polymorphism and hemodialysis on codeine disposition in patients with end-stage renal disease.

Authors:  Hadi Molanaei; Juan Jesus Carrero; Olof Heimbürger; Louise Nordfors; Bengt Lindholm; Peter Stenvinkel; Ingegerd Odar-Cederlöf; Leif Bertilsson
Journal:  Eur J Clin Pharmacol       Date:  2009-11-26       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.